Albert Bourla decentralizes Pfizer’s generative AI deployment model

Pfizer CEO Reverses Course on Generative AI Deployment

Two years after deploying generative technology across the enterprise, Pfizer CEO Albert Bourla found himself grappling with stagnation. Chatting prior to his appearance at the Concordia Annual Summit in New York, the chief executive detailed the late-night reflections that prompted him to reverse course on how the firm deploys generative AI, according to wsj.com.

I spent all my nights before sleep thinking what I did right and what I did wrong, and that didn’t feel good, he said, as reported by wsj.com last month. I wanted to make sure that I see much faster and radical progress, and I was getting frustrated that things are moving fast, but not the pace I wanted.

Dismantling the Centralized Tech Model

Initially, the executive believed that centralizing oversight under dedicated technology specialists was essential for driving meaningful digital transformation. Yet, as AI proficiencies commoditized, he concluded that empowering domain experts yielded better outcomes.

Who better to transform manufacturing than the person who owns manufacturing? The same goes for R&D, marketing, et cetera, Bourla explained.

Decentralizing Operations for Faster Execution

Under the new distributed model adopted a few months ago, leaders closest to specific business operations make the operational calls and answer for workflow alterations, while a central team provides underlying support. This structural adjustment reduced internal pushback and accelerated the pace of operational change.

To prevent breakthrough moments from becoming isolated within specific divisions, Bourla slimmed down his senior leadership team and expanded individual responsibilities. This streamlined group convenes more frequently to manage ongoing challenges at the highest level.

Cross-Functional Clans Ease Administrative Bottlenecks

Further down the corporate hierarchy, the company established cross-functional groups known as clans. For example, the engineers. We have engineers in R&D. We have engineers in manufacturing. We have engineers in digital, Bourla noted. While these professionals remain anchored to their respective departments, shared interests foster substantial internal cross-pollination.

Despite these adjustments, the broader pharmaceutical giant continues to realize tangible efficiencies. Administrative bottlenecks in data reporting and clinical-trial planning have eased significantly. The corporation is initiating 20 Phase 3 studies this year—double the volume of the previous year—spanning critical post-Covid bets in obesity and oncology treatments.

An Evolving Puzzle

Even with these productivity gains, executive leadership acknowledges that the optimal framework for enterprise-wide technology integration remains an evolving puzzle.

I’m not certain about what is the way to go about it, but I have made some choices, which I hope are the right ones, Bourla stated.